Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Idexx Laboratories (NQ: IDXX )

433.96 +1.85 (+0.43%)
Streaming Delayed Price Updated: 2:36 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Idexx Laboratories

< Previous 1 2 3 4 5 6 7 8 9 Next >
Beyond The Numbers: 6 Analysts Discuss IDEXX Laboratories Stock
Via Benzinga
P/E Ratio Insights for IDEXX Laboratories
Via Benzinga
(IDXX) - Analyzing IDEXX Laboratories's Short Interest
Via Benzinga
3 Purrfect Stocks to Buy for the Booming Pet Care Industry
Despite the post-pandemic slowdown, stocks within the pet care industry are good long-term investments because the revenue trend is higher. 
Via InvestorPlace
$1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Stifel: ‘Party Is Just Getting Started’ In This Stock That's Up 80%
Animal-pharma company Elanco Animal Health, once a subsidiary of Lilly, looks especially good with its new treatment for parvovirus in dogs. 
Via Talk Markets
If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,000 Today
Via Benzinga
Examining the Quality Attributes of NASDAQ:IDXX.
Why Quality-Oriented Investors Should Consider NASDAQ:IDXX. 
Via Chartmill
(IDXX) - Analyzing IDEXX Laboratories's Short Interest
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $10,000 Today
Via Benzinga
IDEXX Laboratories Schedules Two Institutional Investor Events
From IDEXX Laboratories, Inc.
Via Business Wire
IDEXX Laboratories Stock Earns IBD Stock Rating Upgrade
On Wednesday, IDEXX Laboratories now stock clears the 80-plus Relative Strength Rating threshold, with a jump from 79 to 83. 
Via Investor's Business Daily
PROCEPT BioRobotics Stock Scores Rising Relative Strength
The Relative Strength (RS) Rating for PROCEPT BioRobotics stock headed into a new percentile Tuesday, as it got a lift from 70 to 77. 
Via Investor's Business Daily
IDEXX Laboratories Inc. (NASDAQ: IDXX) is a Leading Gainer in Monday Morning Trading
Via Investor Brand Network
SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's How Much $100 Invested In IDEXX Laboratories 15 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $100 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth Today
Via Benzinga
How Is The Market Feeling About IDEXX Laboratories?
Via Benzinga
5 Analysts Have This to Say About IDEXX Laboratories
Via Benzinga
Is There An Opportunity To Buy IDEXX Labs, The Animal Diagnostics-Focused Firm Stock After Q3 Performance? Analyst Answers
IDEXX Laboratories Inc (NASDAQ: IDXX) reported Q3 FY23 sales of $915.53 million, missing the consensus of $926.76 million 
Via Benzinga
IDEXX Laboratories Announces Third Quarter Results
From IDEXX Laboratories, Inc.
Via Business Wire
IDEXX Laboratories's Earnings: A Preview
Via Benzinga
This Is What Whales Are Betting On IDEXX Laboratories
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,700 Today
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today
Via Benzinga
IBD's 100 Best ESG Companies For 2023
The companies on our list combine high sustainability scores and top stock ratings. 
Via Investor's Business Daily
IDEXX Laboratories to Release 2023 Third Quarter Financial Results
From IDEXX Laboratories, Inc.
Via Business Wire
3 Stocks Ready to Rocket on These Global Mega Trends
The best stocks to buy right now aren't focused on small, short-term themes. They are companies poised to rocket on global mega trends. 
Via InvestorPlace
IDEXX Labs In The Hot Seat: Analyst Forewarns Dwindling Vet Visits Amid Macro Headwinds Ahead
Stifel analyst Jonathan D. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.